research, development and clinical studies for product candidates. Such
statements involve certain known and unknown risks, uncertainties and
other factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Basilea Pharmaceutica Ltd. is providing this communication as of this
date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com
This press release can be downloaded from www.basilea.com.
References
1. The ceftobiprole phase 3 program is funded in part (up to USD 130 million,
which is approximately 70% of the total estimated program costs) with
federal funds from the U.S. Department of Health and Human Services;
Office of the Assistant Secretary for Preparedness and Response;
Biomedical Advanced Research and Development Authority (BARDA), under
Contract No. HHSO100201600002C.
2. IQVIA, September 2020. In-market sales reported as moving annual total
(MAT) in U.S. Dollar corrected for currency fluctuations.
3. ERADICATE study: ClinicalTrials.gov identifier NCT03138733
4. TARGET study: ClinicalTrials.gov identifier NCT03137173
5. Basilea in-licensed derazantinib from ArQule Inc., a wholly-owned
subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
6. FIDES-01 study: ClinicalTrials.gov identifier NCT03230318
7. FIDES-02 study: ClinicalTrials.gov identifier NCT04045613
8. FIDES-03 study: ClinicalTrials.gov identifier NCT04604132
9. ClinicalTrials.gov identifier NCT02490800
Attachment
Press release (PDF)
https://www.globenewswire.com/Tracker?data=pddCJFD3TzTMgvD1VwXFk5gJ64VckEFCtDoVYI4-n11hZSJCx6e1LCJwB6BquAEu0JEuyzM6fpAfPsvKXQCz8jxp9AG69eALR6FtXqhhFZEoYvjKpS5UpWPh255QKGO1G1W8woMtBgAQ46MnNgOF4C8-OUzWBWJ9Tzan6PsRTo69CGi9kif8fWqIDeJLqHBs
(END) Dow Jones Newswires
February 16, 2021 01:15 ET (06:15 GMT)